Skip to main content
MTRI
NASDAQ Life Sciences

Mentari Posts First Post-Merger Financials: $63.0M Nine-Month Loss, $45.8M Cash, $490M Raised

Arie Shkolnikov · Analysis by Wiseek AI
Sentiment info
Neutral
Importance info
7
Price
$19
Mkt Cap
$982.339M
52W Low
$12.2
52W High
$233
52W Position info
56% above low
Off High info
92% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

MTRI sits 56% above its 52-week low of $12.2.

Summary

Mentari's first post-merger 8-K delivers the acquired company's interim financials: a $63.0 million nine-month net loss, $45.8 million of cash, and roughly $490 million raised in pre-closing financings that management says funds operations into 2029.


Key Events · M&A and Partnerships · MTRI

  • First Post-Merger Financials Filed

    The 8-K attaches Mentari's unaudited condensed consolidated financial statements and MD&A for the three and nine months ended September 30, 2026 — the first public financial disclosure of the merged company.

  • Nine-Month Net Loss of $63.0M

    Net loss was $63.0 million for the nine months ended September 30, 2026 ($32.2 million in Q3 alone), with an accumulated deficit of $82.4 million; operating cash burn was $48.0 million.

  • $490M Pre-Closing Financing Quantified

    Investors bought 215,042,178 shares and 7,317,328 pre-funded warrants for about $490.0 million gross across two tranches ($290.0 million and $200.0 million), converted at the 0.20065 exchange ratio into 29,562,623 shares plus 1,178,898 pre-funded warrants and 13,585,590 shares plus 289,324 pre-funded warrants.

  • Cash Runway Into 2029

    Cash and cash equivalents were $45.8 million at September 30, 2026; management states existing cash plus merger and pre-closing financing proceeds fund operating plans into 2029.


Analysis · MTRI · Life Sciences

Here is the first look at the merged company's actual numbers. Mentari burned $48.0 million of operating cash over nine months and posted a $63.0 million net loss, yet it closed the merger with roughly $490 million of gross pre-closing financing and $45.8 million of cash on the balance sheet at September 30. Management now says the combined cash funds operations into 2029, removing near-term financing risk for a clinical-stage migraine program whose lead asset MT-001 is in Phase 1 with initial data expected mid-2027. The offset is heavy related-party dependence: $13.9 million owed to Paragon and Fairmount, a $50 million 12% convertible note from Fairmount that converted at closing, and Fairmount holding roughly 41.7% of the pre-merger company. Former Mentari holders now own about 99% of the combined company on a fully diluted basis.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MTRI was trading at $19.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $982.3M. The 52-week trading range was $12.20 to $233.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MTRI - Latest Insights